IVERIC bio

IVERIC bio is a biopharmaceutical company focused on the discovery and development of treatment options for retinal diseases with unmet medical needs. The company is developing both therapeutics for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. The company's product candidate Zimura, a complement inhibitor, is a chemically-synthesized, pegylated RNA aptamer. The company's clinical trials for Zimura include: OPH2003, for patients with geographic atrophy secondary to dry age-related macular degeneration; and OPH2005, for the treatment of Stargardt disease.
  • TickerISEE
  • ISINUS46583P1021
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States
Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 14 2021 6:52AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

Wedbush PacGrow Healthcare Conference

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 14 2021 6:52AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

Wedbush PacGrow Healthcare Conference

Wedbush Research

Wedbush Morning Call - Jun 07 2021 6:57AM

Andreas Argyrides ...
  • David Nierengarten
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Robert Driscoll

The Week Ahead in Life Sciences

IVERIC BIO sees an upgrade to Slightly Negative thanks to a better star rating, but the title remains unattractive

The independent financial analyst theScreener just awarded an improved star rating to IVERIC BIO (US), active in the Pharmaceuticals industry. As regards its fundamental valuation, the title receives an improved star rating and now shows 1 out of 4 possible stars. Given its market behaviour as risky, theScreener considers that these elements allowing slightly upgrading its general evaluation to Slightly Negative; the title, however, remains unattractive. As of the analysis date February 16, 2021, the closing price was USD 6.03 and its target price was estimated at USD 3.63.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch